- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 26.08. | JATT mastermind launches latest biotech-focused SPAC via $60M IPO | ||
| 26.08. | Hansoh heralds China's move from 'follower' to 'frontrunner' in biopharma race | ||
| 26.08. | Spyre's rheumatoid arthritis plan toppled by subpar TL1A data | ||
| 26.08. | SK Biopharma pens $795M deal to usher Biohaven's epilepsy therapy towards hoped-for 2029 launch | ||
| 25.08. | Founded by Metsera backers, Sentivera emerges with $1.5B inflammatory disease deal | ||
| 25.08. | Capricor secures reprieve as FDA extends DMD cell therapy review | ||
| 24.08. | TME holds onto $1B dream for brain cancer drug as search for partners nears conclusion | ||
| 24.08. | Spruce's successful FDA talks plant seeds for Q4 filing of ultra-rare disease drug | ||
| 24.08. | Regenxbio gene therapy refiling plan derailed by FDA hold over spine MRI findings | ||
| 24.08. | Roche pens $2.5B pact for Hanmi's clinical-stage obesity drug targeting less-explored mechanism | ||
| 21.08. | Werewolf Therapeutics transforms into Ambros Therapeutics via reverse merger to support phase 3 push for rare disease drug | ||
| 20.08. | Lilly pens deal with Gateway Labs alumni Amplitude for RNA vaccine platform for infectious disease | ||
| 20.08. | Merck-Moderna cancer vaccine win spurs stock jump, speculation of Keytruda-like impact | ||
| 19.08. | Trump looks set to tap White House aide Heidi Overton as next FDA commissioner | ||
| 19.08. | Tolerance Bio jumps into phase 2 with $260M deal for thymus-targeting fusion protein | ||
| 18.08. | Merck and Sarah Cannon team up to boost oncology trial efficiency | ||
| 18.08. | Kolon TissueGene shrinks workforce after pivotal osteoarthritis trial miss | ||
| 18.08. | BioMarin bulks up bone unit with $275M Alesta buyout to challenge AstraZeneca | ||
| 17.08. | Regeneron ends eye disease trial for anti-CD3 antibody following safety review | ||
| 17.08. | Merck KGaA lays off 20 staffers in latest blow to US research team | ||
| 17.08. | Slate Medicines uses Fulcrum Therapeutics to vault onto Nasdaq with $245M financing for migraine trials | ||
| 17.08. | Evaxion scraps solid tumor vaccine to focus on Duke-partnered brain cancer candidate | ||
| 17.08. | Lilly pens $370M deal with OmniAb for ion channel collab, but details remain vague | ||
| 17.08. | AstraZeneca ends phase 3 lung cancer trial after bispecific falls short versus Keytruda | ||
| 14.08. | Skye and Redx form new entity with $125M to advance fibrosis assets |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.